Business Context and Reporting Period
Company: NERVGEN PHARMA CORP.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2026 (Specifically March 13, 2026)
This filing announces a voluntary delisting of the Company's common shares from the TSX Venture Exchange (TSXV), effective at the close of trading on March 16, 2026. Following delisting, shares will continue to trade exclusively on the Nasdaq Capital Market under the symbol "NGEN."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a material change report regarding corporate governance and listing status rather than a financial performance report.
Material Changes
- Delisting: The Company is voluntarily removing its shares from the TSX Venture Exchange.
- Trading Venue: Trading will continue solely on the Nasdaq Capital Market.
- Effective Date: The delisting becomes effective March 16, 2026.
Guidance, Outlook, and Risks
Management Commentary: The filing includes a standard disclaimer stating that the information is summary in nature and should be considered in the context of other SEC filings. The Company undertakes no duty to update or revise this information except as required by law.
Contingencies: The filing incorporates by reference a Material Change Report (Exhibit 99.1) and notes that this Form 6-K is part of a Registration Statement on Form F-10.
Investor Verification Checklist
- Verify the effective date of the TSXV delisting (March 16, 2026).
- Confirm continued trading status on the Nasdaq Capital Market under symbol "NGEN."
- Review the full Material Change Report (Exhibit 99.1) for detailed rationale regarding the delisting.
- Check the status of the Form F-10 Registration Statement (File No. 333-292197) into which this report is incorporated.